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Evidenceofactivebrownadiposetissueinhumanadultssuggeststhatthismaybecomeapharmacologicaltargettoinducenegative
energy balance. We have explored whole-body indirect calorimetry to detect the metabolic eﬀects of thermogenic drugs through
administration of ephedrine hydrochloride and have assessed ephedrine’s merits as a comparator compound in the evaluation
of novel thermogenic agents. Volunteers randomly given ephedrine hydrochloride 15mg QID (n = 8) or placebo (n = 6) were
studied at baseline and after 1-2 and 14-15 days of treatment. We demonstrate that overnight or 23-hour, 2% energy expenditure
(EE) and 5% fat (FO) or CHO oxidation eﬀects are detectable both acutely and over 14 days. Compared to placebo, ephedrine
increased EE and FO rates overnight (EE 63kJ day 2, EE 105kJ, FO 190kJ, day 14), but not over 23h. We conclude that modest
energy expenditure and fat oxidation responses to pharmacological interventions can be conﬁdently detected by calorimetry in
small groups. Ephedrine should provide reliable data against which to compare novel thermogenic compounds.
1.Introduction
Obesity usually develops gradually as a result of a modest
but sustained energy surplus. A continuing positive energy
imbalanceofjust1%predictsabodymassincreaseofaround
1kg per year. Clinical management of obesity presents
a particular challenge because lifestyle interventions are
poorly eﬀective [1–3] and there are few drug targets that
have yielded outstanding clinical eﬃcacy. Theoretically, such
targets could be in systems regulating energy intake or
energy expenditure, although it is clear that these are closely
integrated within the central nervous system (CNS).
Most pharmacological approaches to obesity man-
agement in humans have focussed on reducing energy
intake. Even when pharmacological interventions have been
postulated to increase energy expenditure, it seems that
much of the eﬀect on body weight was mediated through
decreased energy intake [4]. However, it is interesting that
the ephedrine-caﬀeine combination [4] and, more recently,
tesofensine [5], a triple central monoamine uptake inhibitor,
which have been shown to produce weight loss, do have
measurable eﬀects on energy expenditure, though again
most of the weight loss observed appears to be attributable
to eﬀects on energy intake [6]. This demonstrates that
mechanistic speciﬁcity is hard to achieve. This is exempliﬁed
by sibutramine, a drug that predominantly enhances satiety,
but which, in some studies, increases energy expenditure
acutely and reduces the fall in resting energy expenditure
seen during weight loss [7–9], although in others it was
without measurable eﬀect [9, 10]. This contrasts with the
substantial energy expenditure eﬀects of sibutramine in
animal studies [11, 12].2 Journal of Obesity
Thus, three clear messages emerge from the literature.
First, the degree of energy expenditure-related weight loss
thatcanbeinducedpharmacologicallyinrodentsisgenerally
much greater than that seen in humans. Secondly, modest
thermogenic eﬀects in man could make a valuable direct
or indirect contribution to body weight management by
reducing the propensity for weight loss to plateau due to
metabolic compensation [13]. Thirdly, poor mechanistic
speciﬁcity of previous weight loss compounds suggests that
energy expenditure should arguably be included in the
mechanistic studies of developmental compounds.
From this introduction, it will follow that studying the
responses to novel pharmacological interventions requires
measurement of changes in body composition, changes
in energy expenditure, and changes in food intake. Well-
documented reference compounds are of value in providing
positive control.
Demonstrating the eﬃcacy of compounds in early-
phase drug development requires particularly sensitive and
precise measurement techniques. We have recently reported
the potential for quantitative magnetic resonance (QMR)
methodology to enhance the precision of body composi-
tion change measurements [14] and have documented its
precision in a way which will contribute to the design and
powering of our studies of pharmacological agents. Here
we present a complementary analysis of the precision with
which calorimetric methods may be used to detect changes
in energy expenditure and macronutrient oxidation rates.
To provide a pharmacological context for this analysis, we
have adopted ephedrine, an established compound with
documented thermogenic properties, to generate the manip-
ulation of energy expenditure in this study.
Recent observations of active brown adipose tissue
(BAT) in man may oﬀer new targets through which energy
expenditurecontributionstoweightlossanditsmaintenance
maybeenhanced(refs)andmayinvolveattemptstopromote
the development of BAT from precursor cells [15].
We anticipate that our ﬁndings will inform the design of
protocols to evaluate novel therapies in the near future.
2. Methods
The study was conducted at Addenbrooke’s Centre for Clin-
ical Investigation (ACCI), Addenbrooke’s Hospital, Cam-
bridge, UK. Within the ACCI, investigations were under-
taken in the GlaxoSmithKline Clinical Unit in Cambridge
(CUC) and the Wellcome Trust Clinical Research Facility
(WTCRF).
2.1. Participants. Participants were recruited from the GSK
CUC panel of healthy volunteers. All were healthy males,
with body mass index (BMI, weight/height2) ranging from
25 to 30kg/m2. Participants were screened by review of
medical history, physical examination, and laboratory tests.
Exclusion criteria included history of metabolic disorders,
substantial change, or modiﬁcation of body weight, regular
strenuous exercise, or use of recreational drugs. Fourteen
subjects completed this study.
The study was performed in accordance with Good
Clinical Practice guidelines and the 1996 version of the
DeclarationofHelsinki.Protocolswereapprovedbyaninter-
nal GSK review panel, Addenbrooke’s Hospital R&D oﬃce,
the WTCRF Scientiﬁc Advisory Board, and the Cambridge
Local Research Ethics Committee (LREC04/Q0108/6). Each
subject gave written informed consent prior to participation.
2.2. Treatment. The study followed a double-blind, placebo
controlled design. The active treatment was ephedrine
hydrochloride 15mg administered four times per day (E).
Eight participants received ephedrine and six received
placebo in a randomized order.
2.3. Study Design. Participants attended on two occasions
separated by 2 weeks. The days of the study visits are
identiﬁed as follows: Day −1, Day 1, Day 2, Day 14, and
Day 15. Two participants were studied at each visit. Alcohol,
caﬀeine, and strenuous exercise were prohibited 48 hours
prior to the ﬁrst visit and throughout the study.
Participants arrived fasting at 08:00 on Day −1. Breakfast
was given at 09:45 and lunch at 13:30. Following lunch,
body composition was measured by dual-energy X-ray
absorptiometry (DXA; GE Lunar Prodigy, GE Healthcare,
Madison, WI, USA) and by BOD POD (Life Measurement
Inc.,Concord,CA).Dinnerwasservedat19:00.Afterdinner,
participants were ﬁtted with an ActiHeart combined activity
and heart rate monitor (CamNtech Ltd., Cambridge, UK).
The ActiHeart monitors were worn until the end of the visit.
At 20:00, each participant entered a room calorimeter, where
he remained until 09:00 on Day 2.
Participants followed a strictly deﬁned activity protocol
within the calorimeter. During the ﬁrst evening (Day −1),
participants remained sedentary. They prepared for bed at
23:00, and “lights out” was at 23:30. At 07:00 (Day 1),
they were woken for blood pressure measurements, to pass
urine and to provide fasting blood samples. They returned
to bed until 08:00 when basal metabolic rate (BMR) was
measured over 1h. At 9:00, they rose and dressed, and
breakfastwasservedat9:30.Toobtainpostprandialmeasures
of energy expenditure (not reported here), participants
remained recumbent on the bed between 10:00 and 13:00,
but they were free to read or watch television. Lunch
was served at 13:30. After lunch, participants undertook
sedentary activities until a period of cycling exercise at 17:00.
During each exercise period, a work rate of 50 watts was
maintained for 30 minutes, equivalent to 3kJ/min external
work, costing to the subject typically 13kJ/min. Dinner was
served at 19:00. Following this, the ﬁrst treatment dose was
given at 20:00. A further period of exercise began at 21:00.
Participants prepared for bed at 23:00 as on the previous
night. The protocol described above was then repeated
until participants left the calorimeter at 22:00 following the
exercise on the evening of Day 2. During Day 2, ephedrine or
placebo was administered at 07:00, 13:00, 16:00, and 20:00.
At each treatment time point, blood pressure was recorded
and a blood sample was drawn. Treatment administration
continued until the end of the second visit.Journal of Obesity 3
During the second visit, Day 14 events were as those
for Day −1 with the exception that body composition
measurements(DXAandBODPOD)werenotrepeated.Day
15 events were as those for Day 2.
2.4. Calorimetry. The room calorimeters, in the WTCRF, are
comfortable bed-sitting rooms. They provide measures of
oxygen consumption and carbon dioxide production. Urine
passed by the subject is collected and analysed for urea
and creatinine, from which nitrogen excretion is calculated.
From these measures, macronutrient oxidation rates (fat,
CHO, protein) are computed and energy expenditure is
derived. Calculations, calibrations, and performance have
been described in previous publications [16–18].
T h er o o m sa r ea p p r o x i m a t e l y4m× 2.5m in area and
2.15m high and have a window to the outside world.
Two air-lock hatches allow entry of food and exit of urine
samples. A porthole, sealed with a latex sleeve, enables a
participant to present an arm for venepuncture. The rooms
are carpeted and are furnished with a bed, table, armchair,
and desk chair. They have a wash-basin and a caravan-type
ﬂushable chemical toilet. A television with DVD and games
console and a computer with internet access are provided for
recreation. Exercise is performed on a Seca Cardiotest CT100
cycle ergometer (Seca GMBH, Hamburg, Germany).
2.5. Diet. Prior to attendance for the study, each partici-
pant’s daily energy expenditure within the calorimeter was
predicted using an estimate of BMR from the regression
equations of Schoﬁeld [19] scaled to account for sedentary
activity, and with an addition for the cost of programmed
exercise. Diets were prescribed to match these individual
predictions. Diets were presented as three meals of equal
energy content and composition, with 35% of energy as fat,
13% as protein, and 52% as carbohydrate. Decaﬀeinated
drinks were provided ad libitum, but the associated energy
was ﬁxed by the provision of a standardised milk allowance
and low-energy sweeteners.
2.6. Statistical Analysis. Ephedrine was compared with
placebo by comparing the diﬀerence in active treatment
measurements between days or visits with the corresponding
diﬀerence in placebo treatment measurements. Analysis was
performed using the general linear model implemented
in the DataDesk 6.0 statistical analysis application (Data
Description Inc., Ithaca, NY, USA). The signiﬁcance level, α,
was set at 0.05.
3. Results
The physical characteristics of the participants are presented
in Table 1. Mean values were quite well matched between
the ephedrine and placebo participants, with no signiﬁcant
diﬀerence between groups in any measured characteristic.
Variability in repeated measures of energy expenditure
and macronutrient oxidation was explored in the placebo
group. Two repeat intervals were explored: successive days
and two days separated by 14 days. Analysis was performed
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Figure 1: Mean diﬀerences and standard deviations of diﬀerences
between measures of energy expenditure, made overnight and over
23hours,andrepeatedaftera24-houror14-dayinterval.Untreated
(placebo) subjects, n = 6.
−1000
−500
0
500
1000
D
i
ﬀ
e
r
e
n
c
e
i
n
m
a
c
r
o
n
u
t
r
i
e
n
t
o
x
i
s
a
t
i
o
n
(
k
J
)
24h 14d 24h 14d
Overnight 23hours
Fat
Carbohydrate
Protein
Figure 2: Mean diﬀerences and standard deviations of diﬀerences
betweenmeasuresoffat,carbohydrate,andproteinoxidation,made
overnightandover23hours,andrepeatedaftera24-houror14-day
interval. Untreated (placebo) subjects, n = 6.
between 00:00 and 07:00 representing sleep, and over a 23-
hour interval between 22:00 and 21:00 the following day.
Due to a technical problem during the data acquisition on
day 14, data for one placebo subject was excluded from
the 23-hour variability analyses and from the treatment
eﬀect analysis. Figures 1 and 2 illustrate the ﬁndings of
the variability analysis. From this analysis, we estimate that
the methodology has the power to detect the changes in
energy expenditure and macronutrient oxidation presented
in Tables 2(a) and 2(b).
Figure 3 illustrates the concentrations of ephedrine
hydrochloride in the circulation of the actively treated
participants. Though the plasma concentration during the
night following the initial dose was lower than on the4 Journal of Obesity
Table 1: Physical characteristics of ephedrine study subjects.
Study Treated: n = 8P l a c e b o n = 6
Mean SD Mean SD
Age(y) 29.42 3.69 30.60 2.03
Height (m) 1.81 0.07 1.75 0.03
Weight (kg) 86.76 5.01 81.00 3.62
BMI (kg/m2) 26.57 1.48 26.49 1.24
Fat-free mass (kg) 63.70 7.32 62.61 3.30
Fat mass (kg) 23.05 4.04 18.39 5.71
Fat (%) 26.73 5.26 22.52 6.15
Table 2
(a) The predicted change in energy expenditure detectable in response to an intervention in a group of 6 subjects.
Consecutive days change in EE kJ 14-day-apart change in EE kJ
Overnight (7h) 40 38
24h 190 202
(b) The predicted change in macronutrient oxidation detectable in a group of 6 subjects.
Consecutive days change in kJ 14-day-apart change in kJ
Protein CHO Fat Protein CHO Fat
Overnight (7h) 58 107 116 37 76 101
24h 79 237 189 163 212 125
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Figure 3: Circulatingconcentrations of ephedrine hydrochloridein
treated subjects (n = 8). Solid bars: days 1-2; hatched bars days: 14-
15. T indicates administration times.
corresponding night of the second visit, the daytime concen-
trations were similar on both visits.
Figure 4 shows the inﬂuence of ephedrine treatment
on heart rate, measured over 22.5 hours, between 23:00
and 21:30 the next day. Treatment signiﬁcantly increased
heart rate both acutely (5.5beats/min) and chronically
(3.8beats/min)whencomparedtotheplacebotreatedgroup.
Table 3 presents the average macronutrient oxidation
and energy expenditure for all subjects, overnight and over
23 hours, on the untreated day (Day −1). This provides
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Figure 4: Inﬂuence on 22.5-hour average heart rate of acute or
chronic (14 day) treatment with ephedrine hydrochloride (solid
bars) or placebo (open bars).
a context for interpreting the magnitude of the treatment
eﬀects, which are presented in Table 4.
The diﬀerences in overnight energy expenditure and
macronutrient oxidation between ephedrine- and placebo-
treated participants are presented in Table 4(a). Ephedrine
elevated energy expenditure signiﬁcantly relative to placebo
between both the acute- and chronic-treated nights andJournal of Obesity 5
Table 3: Macronutrient oxidation and energy expenditure—means for all subjects in the untreated condition.
Protein (kJ) CHO (kJ) Fat (kJ) Energy (kJ)
Mean SD Mean SD Mean SD Mean SD
Overnight (7h) 358 154 684 220 1033 253 2075 145
23h 1356 240 4463 680 4137 938 9957 942
Table 4
(a) Diﬀerences between ephedrine- and placebo-related changes in overnight macronutrient oxidation and energy expenditure, between treated (days 1 and
14) and untreated (day 0), and between chronic and acute treatments (days 14 and 1)
Interval Protein Carbohydrate Fat Energy
days diﬀerence (kJ) P diﬀerence (kJ) P diﬀerence (kJ) P diﬀerence (kJ) P
1-0 −46.7 .75 −41.4 .86 150.8 .14 62.7 .05
14–0 −95.9 .32 10.8 .98 190.3 .05 105.2 .001
14–1 −46.2 .73 52.2 .78 39.5 .86 42.5 .23
(b) Diﬀerences between ephedrine and placebo treatment eﬀects on changes in macronutrient oxidation and energy expenditure over 23h, from 22:00 to
21:00, between treated (days 1 and 14) and untreated (day 0), and between chronic and acute treatments (days 14 and 1)
Interval Protein Carbohydrate Fat Energy
days diﬀerence (kJ) P diﬀerence (kJ) P diﬀerence (kJ) P diﬀerence (kJ) P
1-0 131.9 .52 14.5 .99 36.7 .99 183.2 .48
14–0 285.8 .06 −61.0 .93 −94.9 .92 129.9 .69
14–1 153.8 .41 −75.6 .90 −161.6 .85 −53.3 .94
the untreated night, but there was no signiﬁcant diﬀer-
ence between acute and chronic nights. The magnitude
of the treatment eﬀect was 3.0% of the group average
untreated overnight energy expenditure (shown in Table 3)
for the acute response and 5.1% for the chronic response.
The energy expenditure increments were associated with
increments in fat oxidation which reached signiﬁcance
when chronic treatment was compared to the untreated
state. There were no signiﬁcant eﬀects of treatment on
carbohydrate or protein oxidation.
Diﬀerencesin23-hourenergyexpenditureandmacronu-
trient oxidation between ephedrine- and placebo-treated
participants are shown in Table 4(b). No treatment eﬀects
reached signiﬁcance, though the changes in energy expen-
diture reﬂected those which were signiﬁcant in the overnight
observations and represented 1.8% and 1.3% for acute and
chronic treatment eﬀects, respectively.
4. Discussion
Weight loss agents may act on both sides of the energy
balance equation, through central anorexigenic eﬀects or
modulation of energy expenditure. The recent resurgence of
interest in BAT as a potential mediator of thermogenesis in
adulthumans[15,20–23]hasrefocussedinterestonthermo-
genic targets for potential antiobesity drugs. Increased ther-
mogenesis might be achieved by targeting BAT with small
molecules or possibly by increasing the number of brown
adipocytes and their related oxidative capacity [24] via either
transdiﬀerentiation of white adipocytes [25] and/or shifting
the developmental fate of adipocyte progenitors [26].
The evaluation of potential thermogenic compounds
requires measures of changes, energy expenditure, macronu-
trient oxidation, and body composition. Modest rates of
body mass reduction yield beneﬁcial clinical outcomes
[27], and so high measurement precision is essential to
identify compounds with favourable proﬁles during early
stages of development. We have recently reported on the
favourableprecisionofQMRforelucidating changesinbody
composition [14]. Now, we have explored the changes in
energy expenditure and macronutrient oxidation induced
by ephedrine administered both acutely and over a 2-week
“chronic” interval, an interval over which we might expect
to be able to detect the beneﬁcial body composition changes
using QMR. We have explored ephedrine as a potential
comparator compound and have documented the sensitivity
with which whole-body indirect calorimetry can detect
modest changes in energy expenditure and macronutrient
oxidation following its administration.
Ephedrinehasbeenshowntohaveacomplexmechanism
of action which includes central sympathetic activation,
direct actions on adrenoreceptors [28], and peripheral
noradrenalin release [29]. Both alone [30] and in com-
bination with caﬀeine [4], it has been shown to increase
thermogenesisinman,withmuchofthisactivitycontributed
by skeletal muscle in addition to BAT [31]. We selected
ephedrine as our test compound in the light of this literature
and, in doing so have extended the literature on what may
well become a valuable “positive control” against which new
compounds are evaluated.
Our study extends the surprisingly limited literature
documenting the eﬀects of ephedrine on energy expenditure6 Journal of Obesity
over the day [30]. Shannon et al. administered ephedrine
50mg three times per day over 24 hours. This was a rather
higher dose than the 15mg × 4 per day which we admin-
istered and which we chose to minimise side eﬀects during
the longer period (14 days versus 1 day) of administration
necessary to study ephedrine’s chronic eﬀects. We found
a 3% increase in overnight energy expenditure after acute
administration, rising to 5.1% after 15 days. This compares
with 8.4% acute response reported by Shannon et al. at
their higher dose. When we analysed the 23-hour data
(Table 4(b)), we found our eﬀects reduced below the level of
signiﬁcance, in both the acute or chronic conditions, to 1.8
and 1.3%. However, Shannon et al. also reported attenuated
24-hour eﬀects, to a just-signiﬁcant 3.6%. Given the robust
response in the overnight measurements, this suggests a
substantial compensation in daytime energy expenditure for
the eﬀects of the ephedrine treatment, at least at the thermo-
neutral temperatures of our studies.
OurstudyextendsthereportofShannonetal.bydemon-
strating that the increment in overnight energy expenditure
was funded by increased fat oxidation, signiﬁcantly so over
the chronic study period. This supports the inference from
early, short-duration resting gas exchange measurements
made on directly-expired air [32]. The recruitment of fat
oxidation seen overnight was not present in the 23 hours
analysis.
The eﬀect of ephedrine on heart rate was signiﬁcant
and was maintained to the end of the 14-day intervention
(Figure 4), suggesting little tachyphylaxis of its cardiac
chronotropic eﬀects during chronic ephedrine administra-
tion. The magnitude of the rise in heart rate is similar
to that seen with sibutramine treatment [33]. The lack of
tachyphylaxis is conﬁrmed by the overnight energy expen-
diture response to ephedrine. Compared to the placebo-
treated group, the energy expenditure of the ephedrine
group was signiﬁcantly elevated during the overnight period
(Table 4(a)). During the ﬁrst night, after a single ephedrine
dose (Figure 3), the elevation was 3%. After 14 days, this
had increased to 5% (P<. 001), by which time circulating
ephedrine levels (at steady state) were quantiﬁable 2 hours
post dose (Figure 3).
Data from the control group in our study extends the
literature documenting the intraindividual variability of 24-
hour or overnight energy expenditure and macronutrient
oxidation rates, both from day-to-day and across longer-
time intervals [34–36]. Though such information is essential
to the design and powering of studies seeking to document
the eﬀects of interventions which target energy expenditure
or macronutrient balance, we found insuﬃcient published
work to enable us to power studies with conﬁdence.
Murgatroyd et al. [37] reported day-to-day variability in
energy expenditure over 14-day continuous conﬁnement
in a calorimeter. Schoﬀelen and Westerterp [35] focussed
on variability in overnight observations. Rumpler et al.
[36] looked at short- and longer-term repeatability, as we
have done here, but the longer-term analysis may have
been inﬂuenced by energy imbalance. None of these reports
extend to analysis of variability in macronutrient oxidation
rates.
Taking data from the placebo-treated group, we have
assessed the repeatability of these measurements and have
derived the sensitivity with which putative changes in
energy expenditure and macronutrient oxidation might be
resolved in an overnight resting state or over a whole
day. In the context of the expenditure and oxidation levels
in Table 3, we estimate that treatment-induced changes in
energy expenditure greater than 2% should be detectable
in a group of six subjects (Table 2(a)), while changes in fat
or carbohydrate oxidation should be detectable at around
the 5% level (Table 2(b)). This suggests that calorimetry
oﬀers suﬃcient sensitivity to detect quite subtle changes
in energy expenditure and fuel selection in response to
pharmacological interventions, changes which nonetheless
could have valuable therapeutic beneﬁts in the medium-to-
long term.
5. Conclusions
In conclusion, highly precise methods are paramount for
detecting subtle diﬀerences in energy expenditure when
evaluatingthethermogenicpropertiesofdrugsthatarebeing
evaluated for the treatment of obesity. Our data conﬁrms
that modest drug eﬀects, where present, can be detected by
whole-body indirect calorimetry, and this technique should
be considered when planning small experimental medicine
studies to evaluate manipulations of energy balance. The
high degree of precision in detecting changes in both
energy expenditure and macronutrient utilisation should
permit early conﬁrmation of preclinical data and proof
of mechanism and help to predict long-term eﬃcacy. We
have conﬁrmed that ephedrine is a reliable thermogenic
compound against which comparison of novel thermogenic
agents may be made after both acute and chronic adminis-
tration.
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